(NEO) NeoGenomics - Overview
Stock: Laboratory, Oncology, Testing, Diagnostics, Molecular
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 68.5% |
| Relative Tail Risk | -20.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -35.69 |
| Character TTM | |
|---|---|
| Beta | 1.095 |
| Beta Downside | 0.580 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.65% |
| CAGR/Max DD | -0.04 |
Description: NEO NeoGenomics January 21, 2026
NeoGenomics, Inc. (NASDAQ: NEO) runs a network of cancer-focused diagnostic laboratories in the United States and the United Kingdom, organized into Clinical Services and Advanced Diagnostics segments. Its customer base spans hospitals, academic centers, pathologists, oncologists, pharmaceutical firms, and other clinical labs, and its test menu includes cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular DNA/RNA profiling, and morphologic pathology analysis.
According to the company’s most recent 10-K (FY 2023), NeoGenomics generated roughly **$1.3 billion in revenue**, representing **≈12 % year-over-year growth**, and reported an **operating margin near 14 %**. The firm posted a modest net loss, reflecting continued investment in capacity expansion and digital platform upgrades. These figures suggest a scaling business, but profitability remains sensitive to reimbursement rates and the cost structure of high-complexity testing.
Key industry drivers that underpin NeoGenomics’ growth outlook include: (1) the accelerating adoption of **precision oncology and companion diagnostics**, which pushes demand for high-throughput molecular and cytogenetic assays; (2) **shifts toward outpatient and community-based testing** that favor specialized reference labs over in-house hospital services; and (3) **pharmaceutical outsourcing of clinical-trial biomarker testing**, providing a steady pipeline of contract work tied to oncology drug development.
For a deeper dive into NeoGenomics’ valuation metrics and peer comparisons, the ValueRay platform offers a concise, data-rich snapshot.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -113.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: 40.11% < 20% (prev 45.62%; Δ -5.51% < -1%) |
| CFO/TA 0.01 > 3% & CFO 13.7m > Net Income -113.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.6m) vs 12m ago 0.76% < -2% |
| Gross Margin: 43.46% > 18% (prev 0.44%; Δ 4303 % > 0.5%) |
| Asset Turnover: 47.03% > 50% (prev 39.25%; Δ 7.78% > 0%) |
| Interest Coverage Ratio: -22.98 > 6 (EBITDA TTM -40.2m / Interest Expense TTM 4.78m) |
Altman Z'' -0.97
| A: 0.21 (Total Current Assets 382.3m - Total Current Liabilities 97.9m) / Total Assets 1.37b |
| B: -0.31 (Retained Earnings -423.9m / Total Assets 1.37b) |
| C: -0.07 (EBIT TTM -109.8m / Avg Total Assets 1.51b) |
| D: -0.79 (Book Value of Equity -423.7m / Total Liabilities 536.5m) |
| Altman-Z'' Score: -0.97 = CCC |
Beneish M -3.03
| DSRI: 0.93 (Receivables 155.8m/151.4m, Revenue 709.2m/644.1m) |
| GMI: 1.00 (GM 43.46% / 43.54%) |
| AQI: 1.13 (AQ_t 0.60 / AQ_t-1 0.53) |
| SGI: 1.10 (Revenue 709.2m / 644.1m) |
| TATA: -0.09 (NI -113.5m - CFO 13.7m) / TA 1.37b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of NEO shares?
Over the past week, the price has changed by -5.31%, over one month by -10.78%, over three months by +9.81% and over the past year by -15.34%.
Is NEO a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NEO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.4 | 26.4% |
| Analysts Target Price | 14.4 | 26.4% |
| ValueRay Target Price | 11.9 | 4.3% |
NEO Fundamental Data Overview February 04, 2026
P/S = 2.246
P/B = 1.8614
P/EG = 3.02
Revenue TTM = 709.2m USD
EBIT TTM = -109.8m USD
EBITDA TTM = -40.2m USD
Long Term Debt = 341.5m USD (from longTermDebt, last quarter)
Short Term Debt = 4.51m USD (from shortTermDebt, last quarter)
Debt = 410.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 246.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.84b USD (1.59b + Debt 410.3m - CCE 164.1m)
Interest Coverage Ratio = -22.98 (Ebit TTM -109.8m / Interest Expense TTM 4.78m)
EV/FCF = -107.9x (Enterprise Value 1.84b / FCF TTM -17.0m)
FCF Yield = -0.93% (FCF TTM -17.0m / Enterprise Value 1.84b)
FCF Margin = -2.40% (FCF TTM -17.0m / Revenue TTM 709.2m)
Net Margin = -16.00% (Net Income TTM -113.5m / Revenue TTM 709.2m)
Gross Margin = 43.46% ((Revenue TTM 709.2m - Cost of Revenue TTM 401.0m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 42.61%)
Tobins Q-Ratio = 1.34 (Enterprise Value 1.84b / Total Assets 1.37b)
Interest Expense / Debt = 0.15% (Interest Expense 603.0k / Debt 410.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -86.8m (EBIT -109.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.91 (Total Current Assets 382.3m / Total Current Liabilities 97.9m)
Debt / Equity = 0.49 (Debt 410.3m / totalStockholderEquity, last quarter 838.3m)
Debt / EBITDA = -6.12 (negative EBITDA) (Net Debt 246.2m / EBITDA -40.2m)
Debt / FCF = -14.44 (negative FCF - burning cash) (Net Debt 246.2m / FCF TTM -17.0m)
Total Stockholder Equity = 870.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.52% (Net Income -113.5m / Total Assets 1.37b)
RoE = -13.03% (Net Income TTM -113.5m / Total Stockholder Equity 870.7m)
RoCE = -9.06% (EBIT -109.8m / Capital Employed (Equity 870.7m + L.T.Debt 341.5m))
RoIC = -6.61% (negative operating profit) (NOPAT -86.8m / Invested Capital 1.31b)
WACC = 7.94% (E(1.59b)/V(2.00b) * Re(9.95%) + D(410.3m)/V(2.00b) * Rd(0.15%) * (1-Tc(0.21)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
Fair Price DCF = unknown (Cash Flow -17.0m)
EPS Correlation: 55.14 | EPS CAGR: 131.3% | SUE: -0.41 | # QB: 0
Revenue Correlation: 98.02 | Revenue CAGR: 11.29% | SUE: 0.91 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.000 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=0.18 | Chg30d=+0.005 | Revisions Net=+1 | Growth EPS=+92.2% | Growth Revenue=+9.8%